Marine Rubat Du Mérac
About Marine Rubat Du Mérac
Marine Rubat Du Mérac is a Senior Legal Counsel currently working at Novartis France, Bristol-Myers Squibb, and UPSA, with extensive experience in healthcare regulation, commercial law, and GDPR regulation.
Current Role at Novartis France
Marine Rubat Du Mérac is currently serving as the Senior Legal Counsel at Novartis France, based in Rueil Malmaison. In this role, she supports multiple business units, including Cardiology, Neurology, Commercial, Communication, and Patient Engagement. Her responsibilities involve handling legal matters related to healthcare regulation, commercial and competition law, anti-gift law, contracting, and GDPR regulation.
Previous Experience at Amgen
Marine Rubat Du Mérac worked at Amgen in various legal roles over a span of eleven years. From 2004 to 2006, she served as a Jurist. She then progressed to the role of Associate Legal Counsel from 2006 to 2008. Subsequently, she was promoted to Senior Legal Counsel and Data Privacy Officer, a role she held from 2008 to 2015.
Legal Career at Law Firms
Marine Rubat Du Mérac has extensive experience working at several law firms. She was a Senior Lawyer at Cabinet Rubat du Mérac SELAS and other law firms from 2016 to 2018 in the Région de Paris. Additionally, she worked at Mathon Law Firm as a Lawyer from 2003 to 2004. Her early career included internships at ODINOT & Associates, Archibald Andersen, and the law firm of Christian HUGLO & Corinne LEPAGE.
Educational Background
Marine Rubat Du Mérac completed her law education at Université Paris Cité, where she studied Droit and achieved III cycles from 1994 to 2000. She later attended the Paris Bar (Ecole du Barreau de Paris), where she studied Law and obtained her CAPA (Certificat d'Aptitude à la Profession d'Avocat) from 2001 to 2002.
Expertise and Initiatives
Marine Rubat Du Mérac has deep expertise in various legal areas, including healthcare regulation, commercial and competition law, anti-gift law, contracting, and GDPR regulation. She has been involved in a three-party partnership with a digital company and hospitals to improve patient pathways and diagnostics. In addition, she has worked on in silico study agreements and collaborations with patient organizations and developed new go-to-market approaches for medicines.